SAN FRANCISCO--(BUSINESS WIRE)--Gemmus Pharma Inc. a privately held biotechnology company developing an improved host-targeted treatment for flu, today announced the appointment of three new directors, Christopher Dunn, M.D. and Louis (Larry) H. Miller Jr., and Independent Director Marc Rubin, M.D. to its Board of Directors.
